CGMP-specific phosphodiesterase type 5 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CGMP-specific phosphodiesterase type 5" in English language version.

refsWebsite

Global rank English rank

23nih.gov

4^th place

12doi.org

2^nd place

5nice.org.uk

3,258^th place

2,666^th place

2ensembl.org

1,626^th place

1,007^th place

2web.archive.org

1^st place

2semanticscholar.org

11^th place

8^th place

1aspetjournals.org

6,663^rd place

5,792^nd place

1fda.gov

447^th place

338^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1nature.com

234^th place

397^th place

1worldcat.org

5^th place

aspetjournals.org (Global: 6,663^rd place; English: 5,792^nd place)

molpharm.aspetjournals.org

Fertel R, Weiss B (July 1976). "Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung". Molecular Pharmacology. 12 (4): 678–687. PMID 183099. Archived from the original (abstract) on 2009-05-10. Retrieved 2008-02-20.

doi.org (Global: 2^nd place; English: 2^nd place)

d'Amati G, Di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, et al. (2002). "Type 5 phosphodiesterase expression in the human vagina". Urology. 60 (1): 191–195. doi:10.1016/s0090-4295(02)01663-1. PMID 12100961.
Uzunov P, Weiss B (September 1972). "Separation of multiple molecular forms of cyclic adenosine-3′,5′-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis". Biochimica et Biophysica Acta (BBA) - Enzymology. 284 (1): 220–226. doi:10.1016/0005-2744(72)90060-5. PMID 4342220.
Weiss B, Hait WN (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annual Review of Pharmacology and Toxicology. 17: 441–477. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360.
Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (August 2008). "Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil". The Journal of Pharmacology and Experimental Therapeutics. 326 (2): 380–387. doi:10.1124/jpet.108.137422. PMID 18456872. S2CID 10202683.
Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, et al. (April 2010). "Oxidative stress regulates left ventricular PDE5 expression in the failing heart". Circulation. 121 (13): 1474–1483. doi:10.1161/CIRCULATIONAHA.109.906818. PMC 3110701. PMID 20308615.
Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. (January 2009). "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice". Circulation. 119 (3): 408–416. doi:10.1161/CIRCULATIONAHA.108.822072. PMC 3791110. PMID 19139381.
Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (March 2018). "Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?". Heart. 104 (15). British Cardiac Society: 1244–1250. doi:10.1136/heartjnl-2017-312865. PMC 6204975. PMID 29519873.
Almasood A, Khairallah H, Shah A, Alabdallah M, Alotaibi M, Al-Moghairi A (2013). "Use of combination of mitral clip and CGMP-specific phosphodiesterase type 5 inhibitor as bridge for cardiac transplantation". Journal of the Saudi Heart Association. 25 (2): 116. doi:10.1016/j.jsha.2013.03.029.
Sarzani R, Giorgi R, Donatelli G, Pietrucci F, Micheli A, Baldoni M, et al. (October 2004). "Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)". International Journal of Impotence Research. 16 (5): 412–417. doi:10.1038/sj.ijir.3901246. ISSN 1476-5489. PMID 15175637.
Henrie AM, Nawarskas JJ, Anderson JR (2015). "Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review". Core Evidence. 10: 99–109. doi:10.2147/CE.S58457. PMC 4636095. PMID 26587013.
Hatzimouratidis K (August 2014). "A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction". Therapeutic Advances in Urology. 6 (4): 135–147. doi:10.1177/1756287214531639. PMC 4054509. PMID 25083163.
Bischoff E (June 2004). "Potency, selectivity, and consequences of nonselectivity of PDE inhibition". International Journal of Impotence Research. 16 (Suppl 1): S11 – S14. doi:10.1038/sj.ijir.3901208. PMID 15224129. S2CID 22178197.

ensembl.org (Global: 1,626^th place; English: 1,007^th place)

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000138735 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000053965 – Ensembl, May 2017

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Viagra". Drug Approval Package. United States Food and Drug Administration. March 27, 1998. Archived from the original on July 28, 2010.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Sildenafil 50 mg film-coated tablets". Medicines.org.uk. Retrieved November 4, 2015.

nature.com (Global: 234^th place; English: 397^th place)

Sarzani R, Giorgi R, Donatelli G, Pietrucci F, Micheli A, Baldoni M, et al. (October 2004). "Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)". International Journal of Impotence Research. 16 (5): 412–417. doi:10.1038/sj.ijir.3901246. ISSN 1476-5489. PMID 15175637.

nice.org.uk (Global: 3,258^th place; English: 2,666^th place)

bnf.nice.org.uk

"Sildenafil". National Institute for Health and Care Excellence. 2018-08-07. Retrieved 2024-05-18.
"Vardenafil". National Institute for Health and Care Excellence. 2011-10-15. Retrieved 2024-05-18.
"Tadalafil". National Institute for Health and Care Excellence. 2012-07-15. Retrieved 2024-05-18.
"Avanafil". National Institute for Health and Care Excellence. 2017-08-24. Retrieved 2024-05-18.

cks.nice.org.uk

"Erectile dysfunction: Phosphodiesterase-5 (PDE-5) inhibitors". National Institute for Health and Care Excellence. 2023-04-04. Retrieved 2024-05-18.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

d'Amati G, Di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, et al. (2002). "Type 5 phosphodiesterase expression in the human vagina". Urology. 60 (1): 191–195. doi:10.1016/s0090-4295(02)01663-1. PMID 12100961.
Uzunov P, Weiss B (September 1972). "Separation of multiple molecular forms of cyclic adenosine-3′,5′-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis". Biochimica et Biophysica Acta (BBA) - Enzymology. 284 (1): 220–226. doi:10.1016/0005-2744(72)90060-5. PMID 4342220.
Weiss B (1975). "Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase". Advances in Cyclic Nucleotide Research. 5: 195–211. PMID 165666.
Fertel R, Weiss B (July 1976). "Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung". Molecular Pharmacology. 12 (4): 678–687. PMID 183099. Archived from the original (abstract) on 2009-05-10. Retrieved 2008-02-20.
Weiss B, Hait WN (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annual Review of Pharmacology and Toxicology. 17: 441–477. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360.
Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (August 2008). "Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil". The Journal of Pharmacology and Experimental Therapeutics. 326 (2): 380–387. doi:10.1124/jpet.108.137422. PMID 18456872. S2CID 10202683.
Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, et al. (April 2010). "Oxidative stress regulates left ventricular PDE5 expression in the failing heart". Circulation. 121 (13): 1474–1483. doi:10.1161/CIRCULATIONAHA.109.906818. PMC 3110701. PMID 20308615.
Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. (January 2009). "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice". Circulation. 119 (3): 408–416. doi:10.1161/CIRCULATIONAHA.108.822072. PMC 3791110. PMID 19139381.
Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (March 2018). "Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?". Heart. 104 (15). British Cardiac Society: 1244–1250. doi:10.1136/heartjnl-2017-312865. PMC 6204975. PMID 29519873.
Sarzani R, Giorgi R, Donatelli G, Pietrucci F, Micheli A, Baldoni M, et al. (October 2004). "Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)". International Journal of Impotence Research. 16 (5): 412–417. doi:10.1038/sj.ijir.3901246. ISSN 1476-5489. PMID 15175637.
Khera M, Goldstein I (June 2011). "Erectile dysfunction". BMJ Clinical Evidence. 2011. PMC 3217797. PMID 21711956.
Henrie AM, Nawarskas JJ, Anderson JR (2015). "Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review". Core Evidence. 10: 99–109. doi:10.2147/CE.S58457. PMC 4636095. PMID 26587013.
Hatzimouratidis K (August 2014). "A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction". Therapeutic Advances in Urology. 6 (4): 135–147. doi:10.1177/1756287214531639. PMC 4054509. PMID 25083163.
Bischoff E (June 2004). "Potency, selectivity, and consequences of nonselectivity of PDE inhibition". International Journal of Impotence Research. 16 (Suppl 1): S11 – S14. doi:10.1038/sj.ijir.3901208. PMID 15224129. S2CID 22178197.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, et al. (April 2010). "Oxidative stress regulates left ventricular PDE5 expression in the failing heart". Circulation. 121 (13): 1474–1483. doi:10.1161/CIRCULATIONAHA.109.906818. PMC 3110701. PMID 20308615.
Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. (January 2009). "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice". Circulation. 119 (3): 408–416. doi:10.1161/CIRCULATIONAHA.108.822072. PMC 3791110. PMID 19139381.
Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (March 2018). "Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?". Heart. 104 (15). British Cardiac Society: 1244–1250. doi:10.1136/heartjnl-2017-312865. PMC 6204975. PMID 29519873.
Khera M, Goldstein I (June 2011). "Erectile dysfunction". BMJ Clinical Evidence. 2011. PMC 3217797. PMID 21711956.
Henrie AM, Nawarskas JJ, Anderson JR (2015). "Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review". Core Evidence. 10: 99–109. doi:10.2147/CE.S58457. PMC 4636095. PMID 26587013.
Hatzimouratidis K (August 2014). "A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction". Therapeutic Advances in Urology. 6 (4): 135–147. doi:10.1177/1756287214531639. PMC 4054509. PMID 25083163.

dailymed.nlm.nih.gov

"Viagra -sildenafil citrate tablet". Daily Med- U.S National Library of Medicine. Retrieved November 5, 2015.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (August 2008). "Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil". The Journal of Pharmacology and Experimental Therapeutics. 326 (2): 380–387. doi:10.1124/jpet.108.137422. PMID 18456872. S2CID 10202683.
Bischoff E (June 2004). "Potency, selectivity, and consequences of nonselectivity of PDE inhibition". International Journal of Impotence Research. 16 (Suppl 1): S11 – S14. doi:10.1038/sj.ijir.3901208. PMID 15224129. S2CID 22178197.

web.archive.org (Global: 1^st place; English: 1^st place)

Fertel R, Weiss B (July 1976). "Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung". Molecular Pharmacology. 12 (4): 678–687. PMID 183099. Archived from the original (abstract) on 2009-05-10. Retrieved 2008-02-20.
"Viagra". Drug Approval Package. United States Food and Drug Administration. March 27, 1998. Archived from the original on July 28, 2010.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Sarzani R, Giorgi R, Donatelli G, Pietrucci F, Micheli A, Baldoni M, et al. (October 2004). "Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)". International Journal of Impotence Research. 16 (5): 412–417. doi:10.1038/sj.ijir.3901246. ISSN 1476-5489. PMID 15175637.

CGMP-specific phosphodiesterase type 5 (English Wikipedia)

aspetjournals.org (Global: 6,663rd place; English: 5,792nd place)

molpharm.aspetjournals.org

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 1,626th place; English: 1,007th place)